Cargando…
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
OBJECTIVE: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. METHODS: After 2 years of do...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682822/ https://www.ncbi.nlm.nih.gov/pubmed/32690791 http://dx.doi.org/10.1212/WNL.0000000000010376 |
_version_ | 1783612753912528896 |
---|---|
author | Hauser, Stephen L. Kappos, Ludwig Arnold, Douglas L. Bar-Or, Amit Brochet, Bruno Naismith, Robert T. Traboulsee, Anthony Wolinsky, Jerry S. Belachew, Shibeshih Koendgen, Harold Levesque, Victoria Manfrini, Marianna Model, Fabian Hubeaux, Stanislas Mehta, Lahar Montalban, Xavier |
author_facet | Hauser, Stephen L. Kappos, Ludwig Arnold, Douglas L. Bar-Or, Amit Brochet, Bruno Naismith, Robert T. Traboulsee, Anthony Wolinsky, Jerry S. Belachew, Shibeshih Koendgen, Harold Levesque, Victoria Manfrini, Marianna Model, Fabian Hubeaux, Stanislas Mehta, Lahar Montalban, Xavier |
author_sort | Hauser, Stephen L. |
collection | PubMed |
description | OBJECTIVE: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. METHODS: After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed. RESULTS: Of patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3–5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (−1.87% vs −2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment. CONCLUSION: Compared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE. CLINICAL TRIAL IDENTIFIERS: NCT01247324/NCT01412333. |
format | Online Article Text |
id | pubmed-7682822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-76828222020-11-24 Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension Hauser, Stephen L. Kappos, Ludwig Arnold, Douglas L. Bar-Or, Amit Brochet, Bruno Naismith, Robert T. Traboulsee, Anthony Wolinsky, Jerry S. Belachew, Shibeshih Koendgen, Harold Levesque, Victoria Manfrini, Marianna Model, Fabian Hubeaux, Stanislas Mehta, Lahar Montalban, Xavier Neurology Article OBJECTIVE: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. METHODS: After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed. RESULTS: Of patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3–5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (−1.87% vs −2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment. CONCLUSION: Compared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE. CLINICAL TRIAL IDENTIFIERS: NCT01247324/NCT01412333. Lippincott Williams & Wilkins 2020-09-29 /pmc/articles/PMC7682822/ /pubmed/32690791 http://dx.doi.org/10.1212/WNL.0000000000010376 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Hauser, Stephen L. Kappos, Ludwig Arnold, Douglas L. Bar-Or, Amit Brochet, Bruno Naismith, Robert T. Traboulsee, Anthony Wolinsky, Jerry S. Belachew, Shibeshih Koendgen, Harold Levesque, Victoria Manfrini, Marianna Model, Fabian Hubeaux, Stanislas Mehta, Lahar Montalban, Xavier Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title | Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title_full | Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title_fullStr | Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title_full_unstemmed | Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title_short | Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension |
title_sort | five years of ocrelizumab in relapsing multiple sclerosis: opera studies open-label extension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682822/ https://www.ncbi.nlm.nih.gov/pubmed/32690791 http://dx.doi.org/10.1212/WNL.0000000000010376 |
work_keys_str_mv | AT hauserstephenl fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT kapposludwig fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT arnolddouglasl fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT baroramit fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT brochetbruno fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT naismithrobertt fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT traboulseeanthony fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT wolinskyjerrys fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT belachewshibeshih fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT koendgenharold fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT levesquevictoria fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT manfrinimarianna fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT modelfabian fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT hubeauxstanislas fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT mehtalahar fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension AT montalbanxavier fiveyearsofocrelizumabinrelapsingmultiplesclerosisoperastudiesopenlabelextension |